Clinical Trial Datasets
References

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr,
Deyton LR, Chodakewitz JA, Fischl MA.AIDS Clinical Trials Group 320 Study Team. A controlled trial
of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4
cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997 Sep 11;337(11):725-33.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA,
Hammer SM. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent
treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
Ann Intern Med. 2001 Dec 4;135(11):954-64.
Browse
Integrated view of ARV, genotypes, RNA and CD4 on 356 patients
Complete Dataset
The Microsoft Access database ACTG320Summary.mdb was created on 356 patients for whom sequences and ARV histories are available and contains tables with treatment, mutations, RNA levels and CD4 counts.
(Note: for some of these patients, the treatment history indicate that they had placebos and this is how the placebos were handled.)
The files contained ACTG320Summary.mdb (the description of each file)
|
2. ACTG 364 clinical trial
| References |
. |
Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team., Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001 Aug 9;345(6):398-407. |
. |
Bosch RJ, Downey GF, Katzenstein DA, Hellmann N, Bacheler L, Albrecht MA; ACTG 364 Study Team, Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz. AIDS. 2003 Nov 7;17(16):2395-6. |
. |
Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA; ACTG 364 Study Team, Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS. 2003 Apr 11;17(6):821-30. |
|
| Sequences |
|
| Browse |
Integrated view of ARV, genotypes, RNA and CD4 on 159 patients
|
| Complete Dataset |
The Microsoft Access database ACTG364Summary.mdb was created on 159 patients for whom sequences are available and contains tables with treatment, mutations, RNA levels and CD4 counts.
|
|
|
3. GART study
| References |
. |
Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC.,
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000 Jun 16;14(9):F83-93. |
|
| Sequences |
|
| Browse |
Integrated view of ARV, genotypes, RNA and CD4 on 153 patients
|
| Complete Dataset |
The Microsoft Access database GARTSummary.mdb was created on 153 patients for whom sequences are available and contains tables with treatment, mutations, RNA levels and CD4 counts.
|
|
|
4. HAVANA study
| References |
. |
Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B; Havana Study Group., Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002 Jan 25;16(2):209-18. |
|
| Sequences |
|
| Browse |
Integrated view of ARV, genotypes, RNA and CD4 on 144 patients
|
| Complete Dataset |
The Microsoft Access database HAVANASummary.mdb was created on 144 patients for whom sequences are available and contains tables with treatment, mutations, RNA levels and CD4 counts.
|
|
|